Evidence map›Paper›PMID 36385887›Full record

ArticleACS omega2022

Formulation and Evaluation of Azithromycin-Loaded Niosomal Gel: Optimization, In Vitro Studies, Rheological Characterization, and Cytotoxicity Study.

Ahlam Zaid Alkilani, Rania Hamed, Hajer Abdo, Lubna Swellmeen, Haneen A Basheer, Walaa Wahdan, Amani D Abu Kwiak

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Design of chitosan-coated CeORSC medicinal chemistry · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Zaleplon nanospanlastics loaded transdermal patches: formulation, optimization, ex-vivo permeation, and in-vivo studies.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ahlam Zaid AlkilaniDepartment of Pharmacy, Faculty of Pharmacy, Zarqa University, Zarqa13110, Jordan.ORCID https://orcid.org/0000-0002-9646-6328
Rania HamedDepartment of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman11733, Jordan.
Hajer AbdoDepartment of Pharmacy, Faculty of Pharmacy, Zarqa University, Zarqa13110, Jordan.
Lubna SwellmeenDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Hashemite University, Zarqa13133, Jordan.
Haneen A BasheerDepartment of Pharmacy, Faculty of Pharmacy, Zarqa University, Zarqa13110, Jordan.
Walaa WahdanDepartment of Pharmacy, Faculty of Pharmacy, Zarqa University, Zarqa13110, Jordan.
Amani D Abu KwiakDepartment of Pharmacy, Faculty of Pharmacy, Zarqa University, Zarqa13110, Jordan.
Zarqa University · JOAl-Zaytoonah University of Jordan · JOHashemite University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several novel, innovative approaches for improving transdermal delivery of BCS class III drugs have been proposed. Despite their great aqueous solubility, BCS class III drugs have the drawback of limited permeability. The objective of the current work was to screen the suitability of niosomes as a nanocarrier in permeation enhancement of azithromycin (AZM) transdermal delivery. Niosomes were prepared by an ether injection method using a nonionic surfactant (Span 60) and cholesterol at different concentrations. The ζ potential (ZP), polydispersity index (PDI), and particle size (PS) of AZM-loaded niosomes were evaluated. The size of the niosomes was found to vary between 288 and 394 nm. The results revealed that the niosomes prepared in a ratio of 2:1 (Span 60: cholesterol) had larger vesicle sizes, but all of them were characterized by narrow size distributions (PDI <0.95). Niosomal gel was successfully prepared using different polymers. The appearance, pH, viscosity, and ex vivo drug release of niosomal gel formulations were all examined. The flow curves showed that the niosomal gel displayed lower viscosity values than its corresponding conventional gels. Niosomal and conventional gels exhibited a domination of the elastic modulus (G') over the viscous modulus (G″) (G'>G″) in the investigated frequency range (0.1-100 rad/s), indicating stable gels with more solid-like properties. Ex vivo skin permeation studies for the niosomal gel show 90.83 ± 3.19% of drug release in 24 h as compared with the conventional gel showing significantly lower (

Identifiers

PMID36385887
PMCPMC9648136
OpenAlexW4307566952

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.